Santen Pharmaceutical (OTCMKTS:SNPHY) Stock Price Up 11.9% – Still a Buy?

Shares of Santen Pharmaceutical Co., Ltd. (OTCMKTS:SNPHY) rose 11.9% during trading on Thursday . The stock traded as high as $11.57 and last traded at $11.57. Approximately 252 shares were traded during trading, a decline of 98% from the average daily volume of 15,812 shares. The stock had previously closed at $10.34.

Wall Street Analyst Weigh In

Separately, Zacks Research raised Santen Pharmaceutical to a “hold” rating in a research note on Monday, April 13th. One investment analyst has rated the stock with a Hold rating, Based on data from MarketBeat, the company presently has an average rating of “Hold”.

Santen Pharmaceutical Stock Up 1.6%

The company has a market cap of $3.78 billion and a PE ratio of 0.10. The company has a 50-day moving average of $10.87 and a 200-day moving average of $10.69.

About Santen Pharmaceutical

Santen Pharmaceutical Co, Ltd. is a Japan‐based specialty pharmaceutical company focused exclusively on ophthalmology. Headquartered in Osaka, Santen engages in the research, development, manufacture and marketing of prescription and over‐the‐counter products for the diagnosis and treatment of eye diseases. Its core product portfolio includes therapies for glaucoma, dry eye, retinal disorders, uveitis and post‐operative care, as well as surgical equipment and diagnostic agents designed to support comprehensive eye care.

With roots tracing back to the late 19th century, Santen has grown from a domestic manufacturer to a global ophthalmic specialist.